Last reviewed · How we verify
Dexamethasone, granisetron & palonosetron
At a glance
| Generic name | Dexamethasone, granisetron & palonosetron |
|---|---|
| Sponsor | Universiti Kebangsaan Malaysia Medical Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (PHASE4)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
- Palonosetron vs Combination of Granisetron and Dexamethasone in Preventing PONV in Laparoscopic Cholecystectomy. (PHASE4)
- Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy (PHASE3)
- Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV (PHASE3)
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: